Article Details

Buy Rating on Benitec Biopharma: Promising Prospects for OPMD Treatment with BB-301

Retrieved on: 2024-06-13 15:30:58

Tags for this article:

Click the tags to see associated articles and topics

Buy Rating on Benitec Biopharma: Promising Prospects for OPMD Treatment with BB-301. View article details on hiswai:

Excerpt

Benitec Biopharma (BNTC) has received a new Buy rating, initiated by Piper Sandler analyst, Yasmeen Rahimi. Yasmeen Rahimi has given his Buy rat.

Article found on: markets.businessinsider.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo